Working for better medicine

We are committed to improving healthcare by researching and developing innovative solutions for disease prevention, management and cure.

Who we are

Our Mission - Italfarmaco SpA

OUR MISSION

Our mission is to create innovative solutions that positively impact patients, society, and the environment.

Our Values - Italfarmaco SpA

OUR VISION

We’re dedicated to promoting pharmaceutical innovation to improve lives, with a particular focus on rare diseases.

Our Vision - Italfarmaco SpA

OUR VALUES

We believe in a commitment to science, in valuing people, and in perseverance, which leads to important results.

An overview of Italfarmaco

Italfarmaco is a private multinational group founded in 1938 and based in Milan, Italy. We produce high-quality medicinal specialties adhering to the highest quality standards. We are committed to improving patients’ lives and overall well-being through pioneering research and development, high-quality production, and global marketing of branded prescription and non-prescription products.

Infographic that offers a general overview of Italfarmaco, through the main numbers of the Group.
Infographic that offers a general overview of Italfarmaco, through the main numbers of the Group.

Therapeutic Areas

Here’s where our expertise brings effectiveness.
Our expertise in developing effective treatments enables us to address complex challenges in key therapeutic areas.

Link to the Rare Diseases page
Link to the Women’s Health section of the Specialty & Consumer Health page
Link to the Cardiometabolic section of the Specialty & Consumer Health page
Link to the Neurology and Psychiatry section of the Specialty & Consumer Health page
Link to the Thrombosis and Critical Ischemia section of the Specialty & Consumer Health page
Link to the Consumer Health section of the Specialty & Consumer Health page

Evolution: how to make treatments more accessible for more patients

Pharmaceutics is a dynamic science, constantly evolving to make every medicine, formula, and application more effective. Our commitment to accessibility drives us to provide significant benefits and enable more people to access targeted and effective treatments. In our four research hubs, we focus on identifying new dosing solutions for approved drugs, repurposing reformulations, and developing APIs to deliver high-quality generic medicines to the market, ensuring that healthcare is more inclusive.

News & Highlights

Discover tha latest news and insights on Italfarmaco Group

  • 2024 - June 28

    Italfarmaco partners with Iktos on Artificial Intelligence to speed drugdiscovery breakthroughs for patients

    Combines AI to increase the potential of novel histone deacetylase (HDAC) inhibitors in the non-oncological field

  • 2023 - September 7

    Duchenne Awareness DAY 2023

    7 September marks World Duchenne Awareness Day (WDAD), a disease in which we as a company are particularly involved.

  • 2022 - September 7

    Duchenne Awareness DAY 2022

    September 7th is World Duchenne Muscular Dystrophy Awareness Day, a disease that sees us, as a company, at the forefront of the search for a drug that can slow down its progression.

  • 2022 - July 26

    Italfarmaco acquires 100% of Lacer, a Spanish pharmaceutical company that is a leader in health care and personal hygiene

    Thanks to this operation, that is subject to the approval of the competition authorities, the Group will reach 1,300 employees in Spain and 3,500 globally, with a consolidated turnover of over 1 billion euros.